Physician profile
Amit Goyal
NPI 1225003676
$3,546.93
in general payments reported to CMS, 2019-2025
30 companies · $709 in 2025
The $709 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $43.57 · 2021: $427 · 2022: $296 · 2023: $411 · 2024: $1,032 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $946.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.21 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $296.80 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $285.23 | 2019-2025 | |
| Shockwave Medical, INC | $208.32 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Genzyme Corporation | $169.01 | 2022-2025 | |
| Ardelyx, INC. | $167.69 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $158.75 | 2024 | Compliance Endokit, Radial Jaw 4 |
| Pfizer INC. | $138.26 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $129.19 | 2024-2025 | Bylvay, Iqirvo |
| Evoke Pharma, INC. | $125.00 | 2022 | |
| Janssen Biotech, INC. | $103.53 | 2023-2025 | Stelara, Tremfya |
| Astrazeneca Pharmaceuticals LP | $71.28 | 2019 | |
| Aimmune Therapeutics, INC. | $66.13 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $45.00 | 2021-2024 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $43.04 | 2021-2024 | |
| Madrigal Pharmaceuticals | $42.93 | 2025 | Rezdiffra |
| Echosens North America, INC. | $39.57 | 2025 | Fibroscan |
| Ferring Pharmaceuticals INC. | $25.59 | 2019 | |
| Shionogi INC | $24.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.23 | 2024 | Gattex |
| Gilead Sciences, INC. | $19.34 | 2025 | |
| Qol Medical, LLC | $19.26 | 2022 | |
| Organon LLC | $17.59 | 2023 | Renflexis, Hadlima |
| Olympus America INC. | $17.43 | 2020 | |
| Lilly USA, LLC | $15.57 | 2024 | Omvoh |
| Amag Pharmaceuticals, INC. | $15.39 | 2021 | |
| Abbott Laboratories | $14.21 | 2025 | Mitraclip |
| Redhill Biopharma INC. | $12.69 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.